Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
The new program includes upstream and downstream process development and large-scale GMP production.
Susanne Kaestner joins the company as Senior Vice President, Quality and member of the Executive Team, and Dr. Thea Boehm as Vice President, Business Development.
The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023
Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
This test analyses samples in VTM directly without the need for RNA extraction step
Subscribe To Our Newsletter & Stay Updated
